Evidence map›Paper›PMID 37361102›Full record

ArticleBioNanoScience2023

Pharmacological Prospects of Morin Conjugated Selenium Nanoparticles-Evaluation of Antimicrobial, Antioxidant, Thrombolytic, and Anticancer Activities.

C Nirmala, M Sridevi, A Aishwarya, Richard Perara, Y Sathiyanarayanan

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioNanoScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

C NirmalaDepartment of Biotechnology, Paavai Engineering College, Paavai Institutions, Namakkal, Tamilnadu India.ORCID 0000-0002-5975-9244
M SrideviDepartment of Biotechnology, Vinayaka Mission's Kirupananda Variyar Engineering College, Vinayaka Mission's Research Foundation (Deemed to be University), Salem, Tamilnadu India.ORCID https://orcid.org/0000-0002-4039-3393
A AishwaryaDepartment of Biotechnology, Vinayaka Mission's Kirupananda Variyar Engineering College, Vinayaka Mission's Research Foundation (Deemed to be University), Salem, Tamilnadu India.
Richard PeraraDepartment of Biotechnology, Vinayaka Mission's Kirupananda Variyar Engineering College, Vinayaka Mission's Research Foundation (Deemed to be University), Salem, Tamilnadu India.
Y SathiyanarayananDepartment of Biotechnology, Vinayaka Mission's Kirupananda Variyar Engineering College, Vinayaka Mission's Research Foundation (Deemed to be University), Salem, Tamilnadu India.
Vinayaka Missions University · INDepartment of Biotechnology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abstract: Selenium nanoparticles (SeNPs) have gained wide importance in the scientific community and have emerged as an optimistic therapeutic carrier agent for targeted drug delivery. In the present study, the effectiveness of nano selenium conjugated with Morin (Ba-SeNp-Mo) produced from endophytic bacteria Graphical Abstract:

Indexed as

AntimicrobialAntioxidantAntiproliferative activityBa-SeNp-MoDNA cleavageThrombolytic

Identifiers

PMID37361102
PMCPMC10169122
OpenAlexW4376115132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.